Johnson & Johnson (JNJ)vsMacroGenics Inc (MGNX)
JNJ
Johnson & Johnson
$266.38
+0.30%
HEALTHCARE · Cap: $640.02B
MGNX
MacroGenics Inc
$4.00
+0.76%
HEALTHCARE · Cap: $270.73M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 55814% more annual revenue ($97.93B vs $175.14M). JNJ leads profitability with a 21.5% profit margin vs -8.3%. MGNX appears more attractively valued with a PEG of 0.01. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
MGNX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$266.38
$125.81 premium
Intrinsic value data unavailable for MGNX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Growing faster than its price suggests
Revenue surging 378.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -331.9% — below average capital efficiency
Earnings declined 70.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : MGNX
The strongest argument for MGNX centers on PEG Ratio, Revenue Growth. Revenue growth of 378.0% demonstrates continued momentum. PEG of 0.01 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MGNX
The primary concerns for MGNX are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MGNX is a hypergrowth play — different risk/reward profiles.
MGNX carries more volatility with a beta of 1.22 — expect wider price swings.
MGNX is growing revenue faster at 378.0% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 42/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →MacroGenics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?